Core Viewpoint - High-yielding dividend healthcare stocks are positioned as attractive investment options for investors seeking passive income, especially with the potential for interest rate cuts on the horizon [2]. Group 1: Investment Rationale - The healthcare sector is characterized by aging populations, recession resilience, and continuous innovation, making it a structurally sound long-term growth area [6]. - The global population over 65 is expected to double in the coming decades, driving sustained demand for medical services and products [8]. - Technological advancements in areas such as gene therapy and AI diagnostics are creating new revenue streams for healthcare companies [5]. Group 2: Company Highlights - **Bristol-Myers Squibb (NYSE: BMY)**: A biopharmaceutical company with a reliable 4.10% dividend, focusing on transformative medicines across various therapeutic areas [9]. - **Healthpeak Properties (NYSE: DOC)**: A REIT investing in healthcare real estate, offering a solid 7.01% dividend and rated highly by analysts [13]. - **Merck (NYSE: MRK)**: A major player in the healthcare industry with a 2.79% dividend, known for its consistent dividend growth over 15 years [16]. - **Pfizer (NYSE: PFE)**: Offers a 6.46% dividend, with strong growth potential from non-COVID products and a promising GLP-1 product launch [21][24]. - **Sanofi (NYSE: SNY)**: A France-based healthcare company with a 4.93% dividend, focusing on patient needs and therapeutic solutions [25].

Core Insights - Pfizer (PFE) and Bristol Myers (BMY) hold significant positions in the oncology market, which is expected to grow due to rising cancer patient numbers [2][3] - Both companies have strong fundamentals and growth drivers, making them attractive investment opportunities [3] Pfizer Overview - Pfizer's oncology portfolio includes various modalities such as small molecules and antibody-drug conjugates (ADCs), targeting multiple cancer types [4] - Key approved drugs include Ibrance, Xtandi, and Padcev, with Ibrance being a major revenue contributor [5] - The acquisition of Seagen in December 2023 enhanced Pfizer's oncology portfolio, adding four ADCs and expected to boost sales in 2025 [6] - Pfizer's oncology biosimilars generated $1.3 billion in sales in 2025, reflecting a 26% year-over-year increase [7] - The company anticipates having eight or more blockbuster oncology medicines by 2030 [8] Bristol Myers Overview - Bristol Myers focuses on immuno-oncology (IO) and has a strong portfolio with drugs like Opdivo and Yervoy [10] - The FDA approval of a new subcutaneous formulation of Opdivo is expected to enhance its market reach [11] - Recent acquisitions, including Mirati and RayzeBio, have expanded its oncology pipeline [12][14] - Krazati, a KRAS inhibitor, is approved for specific lung cancer treatments and is in further development [13] - The collaboration with BioNTech aims to develop bispecific antibodies for various solid tumors [16] Financial Estimates - For 2026, Pfizer's sales are estimated to decrease by 2.51%, while earnings per share (EPS) are expected to decline by 7.76% [17] - In contrast, Bristol Myers' sales are projected to decrease by 2.44%, but EPS is expected to increase by 1.79% [19] Price Performance and Valuation - Year-to-date, Pfizer's shares have increased by 2%, while Bristol Myers' shares have decreased by 1.5% [22] - In terms of valuation, Bristol Myers trades at a forward P/E ratio of 9.49, slightly higher than Pfizer's 9.04 [22] - Pfizer offers a higher dividend yield of 6.47% compared to Bristol Myers' 4.27% [23] Investment Consideration - Both companies are seen as safe investments in the pharma/biotech sector, but Pfizer is currently viewed as a better pick due to its attractive valuation and diversified portfolio [24][26]

Summary of Bristol-Myers Squibb Company (NYSE:BMY) FY Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (BMY) - **Event**: TD Cowen's 46th Annual Healthcare Conference - **Date**: March 02, 2026 Key Points Industry and Market Dynamics - **2025 Performance**: Strong performance with good momentum into 2026, particularly from growth portfolio products like REVLIMID, Breyanzi, and CAMZYOS [3][4] - **Headwinds**: Full generics for REVLIMID and POMALYST are now in the market, impacting legacy portfolio revenue, but significant growth is expected from ELIQUIS [3][4] - **Operating Expenses**: Disciplined management of operating expenses, with a normalization expected in 2026 after higher expenses in the second half of 2025 due to partnerships and acquisitions [4][5] Product Performance - **CAMZYOS**: Annualized over $1 billion in sales, with consistent increases in new patients and prescribers, indicating strong market adoption despite competition [6][7] - **Opdivo Qvantig**: Positive performance with expectations to achieve a 30%-40% conversion rate by 2028, improving practice efficiency and patient experience [8][9] - **Cobenfy**: Good progress in its first year, with a focus on increasing prescriber adoption and upcoming data from a phase 4 switching study expected to enhance market penetration [10][11] Upcoming Trials and Data Readouts - **Alzheimer's Disease Psychosis Trials**: Three studies (ADEPT 1, 2, and 4) are expected to read out by the end of 2026, with confidence in the product's efficacy based on previous studies [16][17] - **Milvexin**: Anticipated data readouts in SSP and AFib by the end of 2026, with potential to become a new standard of care in atrial fibrillation due to a better bleeding profile compared to ELIQUIS [27][28] Future Growth Potential - **Admilprant**: Positioned for significant market potential in IPF and PPF, with expectations that the market could grow from $4 billion to between $8 billion and $10 billion due to improved diagnosis and treatment rates [36][38] - **Pipeline Assets**: Multiple assets expected to read out by the end of 2026, including Cobentfy, Milvexin, Iberidone, and Ibertamide, all showing strong commercial potential [33][35] Strategic Focus - **Long-term Growth Strategy**: The company aims to be the fastest-growing in the industry by the end of the decade, with a focus on sustainable growth through a diverse pipeline of products [51][52] - **Intellectual Property Defense**: Commitment to vigorously defend IP for key products like Opdivo, with a conservative planning date for loss of exclusivity set for December 2028 [43][44] Conclusion - **Overall Outlook**: Bristol-Myers Squibb is positioned for strong growth with a robust pipeline and strategic focus on long-term sustainability, aiming to leverage upcoming data readouts and market opportunities to enhance its competitive position in the pharmaceutical industry [52][53]

Core Viewpoint - Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company with a market cap of $124.4 billion, focusing on innovative medicines across various therapeutic areas [1]. Company Overview - BMY operates in oncology, hematology, immunology, cardiovascular disease, and neuroscience, with notable products including Opdivo, Eliquis, Revlimid, and Yervoy [1]. - The company is classified as a "large-cap" stock, serving patients through a wide commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies [2]. Stock Performance - BMY shares have decreased by 2.2% from their 52-week high of $63.33, but have increased by 25.2% over the past three months, outperforming the Nasdaq Composite's decline of 2.5% during the same period [3]. - Year-to-date, BMY stock is up 14.3%, while the Nasdaq Composite has seen a decrease of 2.6%. However, over the past 52 weeks, BMY shares have only risen by 4.9%, lagging behind the Nasdaq's return of 22.1% [6]. Financial Outlook - On February 5, BMY shares rose by 3.3% after the company projected 2026 revenue between $46 billion and $47.5 billion, exceeding Wall Street expectations, and adjusted EPS of $6.05 to $6.35, also above consensus estimates [7]. - The management's outlook includes a forecasted revenue growth of 10% to 15% for Eliquis in 2026, despite challenges from Medicare price negotiations [7]. - Q4 2025 results showed adjusted EPS of $1.26, revenue of $12.5 billion, and a 9% increase in Opdivo sales to $2.69 billion, alongside $1 billion achieved from a planned $2 billion cost-cutting program [8].

Core Viewpoint - The article emphasizes the importance of high-yield dividend stocks for Baby Boomers seeking reliable income during retirement, especially in light of the modest Social Security cost-of-living adjustment of 2.8% for 2026, which translates to about $56 per retiree per month [1]. Group 1: Dividend Stocks Overview - The article identifies five high-yield dividend stocks that are considered safe and suitable for long-term holding, all offering dividends higher than the 10-year Treasury note's 4.1% [1]. - Since 1926, dividends have contributed approximately 32% to the total return of the S&P 500, highlighting their significance alongside capital appreciation [1]. - A study indicates that dividend stocks delivered an annualized return of 9.18% from 1973 to 2023, significantly outperforming non-payers, which returned 3.95% [1]. Group 2: Featured Companies - **Bristol Myers Squibb (NYSE: BMY)**: A biopharmaceutical company with a reliable 4.16% dividend, focusing on innovative medicines across various therapeutic areas. Guggenheim has a Buy rating with a target price of $72 [1]. - **Comcast (NYSE: CMCSA)**: A telecommunications and media conglomerate offering a 4.15% dividend, operating through multiple segments including media and connectivity services. TD Cowen has a Buy rating with a target price of $39 [1]. - **Ford (NYSE: F)**: An automotive giant with a 4.33% dividend, involved in the development and servicing of a range of vehicles. J.P. Morgan has an Overweight rating with a target price of $15 [2]. - **General Mills (NYSE: GIS)**: A global food manufacturer with a 4.98% dividend, known for its diverse product offerings. Piper Sandler has an Overweight rating with a target price of $60 [2]. - **Verizon (NYSE: VZ)**: A telecommunications company providing a 5.53% dividend, with a strong interest coverage ratio of 4.6× to 5.0×, indicating a solid capacity for dividend payments. Citigroup has a Buy rating with a target price of $450 [2].

Core Insights - Merck & Co. (MRK) and Bristol Myers Squibb (BMY) are significant players in the pharmaceutical industry with diverse product portfolios [1][2] - Merck is recognized for its leadership in oncology, while Bristol Myers focuses on breakthrough therapies across multiple therapeutic areas [1][2] Merck (MRK) Overview - Merck has over six blockbuster drugs, with Keytruda accounting for 54% of total sales in 2025, driving revenue growth [3][4] - Keytruda's sales increased by approximately 7% in 2025, benefiting from its approval for various oncology indications [4] - The FDA approved Keytruda Qlex for subcutaneous administration in September 2025, with peak sales targeted at $35 billion by 2028 [5] - Other oncology drugs like Welireg, Lynparza, and Lenvima are contributing to growth, alongside a strong launch of Winrevair in pulmonary arterial hypertension [6] - Merck is enhancing its vaccine portfolio, particularly with the new 21-valent pneumococcal conjugate vaccine, Capvaxive [7] - The company has around 80 ongoing late-stage studies, expecting over $70 billion in potential commercial opportunities by the mid-2030s [8] Bristol Myers Squibb (BMY) Overview - BMY's growth portfolio includes key brands such as Opdivo, Yervoy, and Reblozyl, with a strong oncology focus [12] - Opdivo's consistent label expansion has maintained its momentum, and the approval of Opdivo Qvantig has strengthened its franchise [13] - BMY's Reblozyl sales exceed $2 billion annually, and strong performance in cardiovascular drug Camzyos has boosted revenues [14] - However, legacy drugs face significant generic competition, with expected sales declines of 12-16% in 2026 [15] - BMY is pursuing strategic acquisitions and collaborations, including a recent agreement with BioNTech to co-develop a bispecific antibody [16][17] - The company aims for $2 billion in annualized cost savings by the end of 2027, having achieved approximately $1 billion in savings in 2025 [18] Financial Performance and Valuation - MRK's 2026 sales are estimated to increase by 2.59%, but EPS is expected to decline by 38.75% [20] - BMY's 2026 sales are projected to decrease by 2.32%, while EPS is expected to increase by 0.33% [20] - MRK shares trade at 21X forward earnings, while BMY trades at 9.74X, with the industry average at 18.74X [24] - BMY offers a higher dividend yield of 4.22% compared to MRK's 2.79% [25] Investment Outlook - BMY is currently viewed as a stronger near-term investment option compared to MRK, which faces multiple headwinds [9][30] - BMY's strategic initiatives and new drug approvals position it favorably against MRK's challenges, including declining sales of Gardasil and competitive pressures on Keytruda [27][30]

Core Insights - Bristol-Myers Squibb Company (BMY) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.26, exceeding the Zacks Consensus Estimate of $1.15, but down from $1.67 in the same quarter last year [1] - Total revenues reached $12.5 billion, surpassing the Zacks Consensus Estimate of $12.25 billion, and reflecting a 1% increase from the previous year [1] - The stock price increased following the better-than-expected quarterly results [1] Financial Performance - BMY's shares have increased by 28.5% over the past six months, while the industry has grown by 43.8% [2] - U.S. revenues remained flat year over year at $8.56 billion, while international revenues rose by 5% to $3.94 billion [3] - The Growth Portfolio revenues increased by 16% to $7.39 billion, primarily driven by immuno-oncology drugs like Opdivo [6][7] - The Legacy Portfolio revenues decreased by 15% to $5.11 billion, impacted by generic competition on key drugs, despite an 8% increase in Eliquis sales to $3.45 billion [11] Key Drug Performance - Opdivo sales increased by 9% year over year to $2.69 billion, surpassing estimates [8] - Yervoy contributed $810 million, up 20% year over year, and Reblozyl sales surged 22% to $666 million [9] - Breyanzi sales rose by 49% to $392 million, while Camzyos sales skyrocketed by 59% to $353 million [10] Cost and Margin Analysis - Adjusted gross margin decreased to 71.9% from 74% in the previous year due to a change in product mix [14] - Adjusted research and development expenses declined by 8% to $2.56 billion, and adjusted marketing, selling, and administrative expenses decreased by 1% to $2.09 billion [15] Future Guidance - For 2026, BMY provided revenue guidance of $46-$47.5 billion, supported by the Growth Portfolio's strong performance [17] - The company expects adjusted earnings to be in the range of $6.05-$6.35 for the full year, with the Zacks Consensus Estimate for 2026 EPS at $6.08 [17] Pipeline Updates - In December 2025, the FDA approved Breyanzi for adult patients with relapsed or refractory marginal zone lymphoma [18] - A supplemental biologics license application for Opdivo in combination with other drugs for Hodgkin lymphoma is under priority review, with a decision expected by April 8, 2026 [19]

Core Insights - Bristol Myers Squibb reported fourth-quarter 2025 revenues of $12.50 billion, exceeding the consensus estimate of $12.281 billion, marking a 1% year-over-year increase [1] - The company highlighted significant progress in 2025, with a strong Growth Portfolio and a robust balance sheet, allowing for continued investment in growth drivers [1] Financial Performance - Adjusted earnings for Bristol Myers Squibb were reported at $1.26, surpassing the consensus of $1.11, although this reflects a 25% decline due to acquired IPRD charges and licensing income [2] - The Growth Portfolio generated revenues of $7.4 billion, a 16% increase (15% at constant currency), primarily driven by the immuno-oncology portfolio, Camzyos, Breyanzi, and Reblozyl [3] - Legacy Portfolio revenues decreased to $5.1 billion, a 15% decline (16% Ex-FX), with increased demand for Eliquis offset by generic impacts and higher U.S. government channel rebates [3] Product Sales - Eliquis sales reached $3.45 billion, an 8% increase [4] - Opdivo sales increased by 9% to $2.69 billion, while Orencia generated $1.01 billion in sales, up 1% [4] - Yervoy sales rose by 20% to $810 million, and Reblozyl saw a 22% increase in quarterly sales to $666 million [4] Future Outlook - For fiscal 2026, Bristol Myers Squibb expects adjusted earnings of $6.05-$6.35 per share, compared to the consensus of $6.02 [5] - The company anticipates 2026 sales of approximately $46 billion-$47.50 billion, exceeding the consensus of $44.16 billion, with a projected revenue decline of 12-16% for the Legacy Portfolio, partially offset by the Growth Portfolio [5] - Global Eliquis revenues are expected to increase by 10%-15% in 2026 [5] - The company projects a gross margin of around 69-70%, influenced by product mix changes [6]

Core Insights - Bristol-Myers Squibb Company (BMY) has a market capitalization of $113.7 billion and focuses on innovative medicines across various therapeutic areas including oncology and immunology [1] Financial Performance - BMY is expected to report an adjusted EPS of $1.65 for fiscal Q4 2025, reflecting a 1.2% decrease from $1.67 in the same quarter last year, although it has consistently exceeded Wall Street's estimates in the past four quarters [2] - For fiscal 2025, analysts project an adjusted EPS of $6.53, representing a significant increase of 467.8% from $1.15 in fiscal 2024 [3] - The company reported a stronger-than-expected Q3 2025 adjusted EPS of $1.63 and a revenue increase of 3% to $12.2 billion, with a notable 18% growth in its Growth Portfolio revenue to $6.9 billion [5] Stock Performance - BMY stock has declined by 1.7% over the past 52 weeks, underperforming the S&P 500 Index, which gained 17.7%, and the State Street Health Care Select Sector SPDR ETF, which rose by 12% during the same period [4] - Following the Q3 2025 results, BMY shares increased by 7.1% on October 30 [5] Analyst Ratings - The consensus rating for BMY stock is "Moderate Buy," with 29 analysts providing coverage, including nine "Strong Buys," one "Moderate Buy," 18 "Holds," and one "Strong Sell" [6] - BMY is currently trading above the average analyst price target of $56.17 [6]

Financial Data and Key Metrics Changes - The company reported a strong year in 2025, with over 50% of the business transitioning to a growth portfolio that grew by 18% in the most recent quarter [23] - The growth portfolio now includes four products that are annualizing over $1 billion, with Reblozyl annualizing over $2 billion [23][24] - The company achieved a reduction in its expense base from $17.8 billion last year to $16.5 billion this year, with a target of an additional $1 billion in savings for 2026 and 2027 [26][27] Business Line Data and Key Metrics Changes - Cobenfy, a product for schizophrenia, has surpassed 2,700 TRXs weekly and is approaching 3,000 TRXs, significantly exceeding other recent schizophrenia launches [10][11] - Camzyos is annualizing over $1 billion, with expectations for continued significant growth as awareness and diagnosis rates improve [76] - The company is focusing on expanding its pipeline with multiple studies in areas such as Alzheimer's disease, bipolar disorder, and autism irritability [17][21] Market Data and Key Metrics Changes - The company has established a strong access position in Medicaid, Medicare, and commercial settings for Cobenfy, which is critical given the dominance of government payers in this space [10] - The launch of Cuvantic has seen a strong conversion from IV to subcutaneous administration, with expectations that 30%-40% of the IV business will convert by 2028 [44] Company Strategy and Development Direction - The company aims to continue driving its growth portfolio and executing against its pipeline, with a focus on operational efficiencies and cash flow generation [25][27] - The company is leveraging AI to enhance efficiency in drug development and manufacturing processes, which is expected to drive shareholder value [29][30] - The company is actively seeking partnerships and acquisitions in therapeutic areas with high unmet needs, particularly in immunology and oncology [39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory and operational efficiencies, with a strong cash position of $17 billion at the end of Q3 [28] - The company is optimistic about upcoming data readouts and the potential for new product launches, particularly in the areas of atrial fibrillation and Alzheimer's disease [66][70] Other Important Information - The company is engaging with policymakers on tariff and healthcare policy issues, emphasizing the importance of access to medicines and the normalization of cost differentials [94][95] - The company has implemented direct-to-patient initiatives, significantly reducing costs for patients, which aligns with broader industry trends [97][98] Q&A Session Summary Question: Can you discuss the recent developments in the COVID study? - The company announced that the ADEPT 2 study will continue with additional patient enrollment after addressing irregularities found during clinical trial site reviews [5][6] Question: What is the current status of Cobenfy in the market? - Cobenfy has achieved strong access in Medicaid, Medicare, and commercial settings, with TRXs approaching 3,000 weekly, indicating significant market traction [10][11] Question: How is the company leveraging AI for efficiencies? - AI is being used to enhance drug development processes, improve manufacturing efficiency, and streamline internal operations, which is expected to drive shareholder value [29][30] Question: What are the company's plans for future product development? - The company has multiple studies underway in various therapeutic areas, including Alzheimer's disease and bipolar disorder, and is confident in the potential for positive outcomes [17][21] Question: How is the company addressing the competitive landscape in oncology? - The company is focusing on partnerships and acquisitions in areas with high unmet needs, particularly in immunology and oncology, to strengthen its market position [39][40]